Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non-Small Cell Lung Cancers from the PHAROS Study.

Cancer research communications - 1 Jul 2026

Riely Gregory J, Martini Jean-François, Pantoja Galicia Norberto, Tunquist Brian, Wilner Keith, Huang Richard S P, Guo Cui, Deng Shibing, Meng Wei, Kiely Jimmy, Zhou Linda, Smith David L, Hartman Mark, Cui Chenming, Rifi Nada, Johnson Bruce E, Tsao Anne S

Abstract excerpt

The detection of biomarkers in blood or tumor tissue samples may affect the efficacy of targeted therapy in patients with non-small cell lung cancer (NSCLC). The FoundationOne Liquid CDx (F1LCDx) and tissue FoundationOne CDx (F1CDx) companion diagnostic tests were approved by the US Food and Drug Administration to identify patients with BRAF V600E-mutant metastatic NSCLC who may benefit from encorafenib combined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carbamates

Share to Carcinoma, Non-Small-Cell Lung

Share to Circulating Tumor DNA

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 42391424
DOI: 10.1158/2767-9764.CRC-26-0102
PMCID: PMC13416939

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non-Small Cell Lung Cancers from the PHAROS Study.PMID 42391424Read ↗

Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.Semantic proximity Read ↗

Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer.Semantic proximity Read ↗

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.Semantic proximity Read ↗

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.Semantic proximity Read ↗

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study.Semantic proximity Read ↗

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.Semantic proximity Read ↗

Radiomic Analysis and Liquid Biopsy in Preoperative CT of NSCLC : An Explorative ExperienceSemantic proximity Read ↗

Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.Semantic proximity Read ↗

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatmentSemantic proximity Read ↗

Predicting Disease Progression in Inoperable Localized NSCLC Patients Using ctDNA Machine Learning Model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.